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Activin-A is a member of transforming growth factor-β (TGF-β) superfamily of cytokines 
which includes TGF-βs, Activins, Nodal, bone morphogenetic proteins (BMPs), growth 
and differentiation factors (GDFs) and anti-Mullerian hormone (AMH). TGF-β, Activin 
and Nodal are known to activate SMAD2/3, while BMPs and GDFs are known to activate 
SMAD1/5/8 signaling pathways. Activin-A binds to type II transmembrane serine 
threonine kinase receptor (ActRIIA or ActRIIB), which in turn activates type I receptor 
(ActRIB) leading to phosphorylation of SMAD2/SMAD3. Upon phosphorylation, 
SMAD2/3 forms a complex with SMAD4, which then translocates to nucleus. In the 
nucleus, SMAD2/3/4 complex, along with other co-factors regulates expression of a large 
number of genes.  
Unlike TGF-β, role of Activin in cancer is not well understood. Activin has been shown 
to be overexpressed in several cancers including metastatic prostate cancer, colorectal 
cancer, lung cancer, hepatocellular carcinoma and pancreatic cancer. Activin signaling 
has been shown to promote aggressiveness of esophageal squamous cell carcinoma and 
enhancing skin tumorigenesis and progression. Nodal, which binds to the same set of 
receptors, has also been shown to be overexpressed in several cancers. However, role of 
Activins in breast cancer progression is not well studied. Activin is expressed by normal 
breast epithelium and is known to play a role in mammary gland development. Earlier, a 
study had reported downregulation of Activin signaling in breast tumors. On the contrary, 
increased serum level of Activin has been reported in women with metastatic breast 
cancers. It is pertinent to mention here that TGF-β, which has been implicated in the 
progression and metastatic spread of breast cancers, also functions through the same set 
of downstream effectors- SMAD2 and SMAD3. Hence we wanted to evaluate the status 
of Activin signaling pathway in breast tumors and investigate its functional role in cancer 
progression.     
Gene expression profiling of 80 breast tumors and 20 normal samples was earlier 
performed in our laboratory revealed overexpression of INHBA in tumors compared to 
normal tissue samples. An independent set of 30 tumor and 15 normal samples were used 
to verify these results. Real-time PCR analysis revealed around 11.31 fold upregulation 
(p<0.001) of INHBA in breast tumors in comparison to normals. While no change in 
expression of INHA was observed, INHBB was found to be significantly downregulated 
in tumor samples. These results indicated upregulation of Activin-A in breast tumors. 
Further, a significant upregulation of ACVR2A and SMAD2 which act as signal 
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transducers of Activin signaling pathway, was observed in breast tumors. Interestingly, 
while an increase in the expression of TGF-β1 was observed, TGFBR2 was found to be 
significantly downregulated in breast tumors. In addition, PCR analysis revealed 
significant downregulation of FST, β-glycan, IGSF1 and IGSF10, which act as negative 
regulators of Activin signaling pathway. Functional antagonism between TGF-β/Activin 
and BMP signaling pathway has been shown in both development and disease. Further 
analysis revealed that various BMPs including BMP2, BMP4 and BMP6 are 
downregulated in breast tumors compared to normal tissue samples. Various components 
and regulators of BMP signaling pathway were also found to be deregulated, indicating 
suppression of BMP signaling in breast tumors. To evaluate whether Activin signaling is 
active in breast tumor cells, immunohistochemistry with another set of 13 normal and 29 
tumor samples was performed. Immunohistochemistry analysis revealed that most of the 
tumors have higher levels of Activin-A compared to normals tissues. Interestingly, no 
significant changes in expression of Activin-A was observed between normals and low 
grade tumors, suggesting that Activin-A may play an important role towards the late 
stages of the disease. In good correlation, breast tumors showed increased phospho 
SMAD2 and phospho SMAD3 levels compared to normal tissues. Also, in the same set of 
tumors, BMP2 staining showed a reduced expression pattern compared to normal tissues. 
Expression of inhibin in some normal and breast tumor samples revealed that most of the 
tumor samples have lower levels of inhibin compared to normal tissues. 
In order to understand the role of Activin-A in cancer progression, a panel of cell lines 
was selected. Treatment of cells with Activin-A resulted in activation of canonical SMAD 
as well as non-canonical Erk1/2 and PI3K signaling pathways. However, Activin-A 
treatment did not lead to activation of TAK1/p38 MAPK pathway. To begin with, it was 
important to evaluate effect of Activin-A on proliferation of various cell lines. Primarily, 
SMAD2/3 signaling pathway inhibits proliferation of normal epithelial cells, and hence, it 
is considered to have a tumor suppressive role.  owever, this signaling pathway remains 
intact in most (  98%) of the breast cancers. BrdU incorporation assay showed that 
Activin-A does not promote proliferation of cells under monolayer culture conditions. 
However, soft agar assay results showed that Activin signaling promotes anchorage 
independent growth of cancer cells. TGF-β is widely known as an inducer of epithelial 
mesenchymal transition (EMT). Also, EMT is considered to be a prerequisite for 
epithelial cells to undergo migration and invasion. During EMT, cells loose epithelial 
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characteristics and acquire mesenchymal features along with cytoskeletal rearrangement. 
Treatment of cells with Activin-A resulted in downregulation of E-cadherin and 
upregulation of various mesenchymal markers. In addition, confocal microscopy imaging 
revealed a mesenchymal morphology of cells treated with Activin-A. Also, collagen gel 
contraction assay results indicated that Activin-A enhances the contractile property of 
HaCaT cells significantly. Cells undergone EMT are believed to acquire migratory and 
Invasive behaviour. In agreement with this, both scratch assay and trans-well migration 
assay showed that Activin-A enhances the migration of various cell lines. Further, Trans-
well matrigel invasion assays were performed to assess how Activin affects invasion of 
various cancer cells. Matrigel invasion assay results showed that Activin-A enhances 
invasion of various cancer cell lines significantly. Also, RT-PCR, zymography and 
Luciferase assay results showed that Activin-A induces MMP2 expression. As described 
earlier, Activin-A activates both canonical as well as non canonical signaling pathways. 
In this direction, it was interesting to investigate the contribution of SMAD signaling 
pathway in pro-tumorigenic actions of Activin-A. Inhibiting SMAD3 activity either by its 
stable knockdown or by using a SMAD3 specific small molecule inhibitor revealed that 
Activin-A regulation of EMT markers is SMAD3 dependent. Further, it was observed that 
SMAD3 contributes significantly in mediating Activin-A induced migration and invasion. 
Hence, it is likely that SMADs may play an important role in breast tumor progression. 
Next, stable overexpression of Activin-A in MCF-7 or its knockdown in MDA-MB-231 
and H460 cells was performed to assess the effect of Activin-A on the behaviour of these 
cells. BrdU assay indicated no change in proliferation of cells upon overexpression or 
knockdown of Activin-A. However, soft agar assay results showed that Activin-A 
expression affects anchorage independent growth of these cells. MCF-7 cells are 
generally considered to be less aggressive in their tumor forming ability. Activin-A 
overexpressing MCF7 cells and control cells were respectively injected into right and left 
flank of immunocompromised mice and followed till the tumors reached to a prominent 
size. Our results show that Activin-A overexpressing MCF-7 cells have better tumor 
forming ability in comparison to control cells.  In contrast to MCF-7 cells, MDA-MB-231 
cells are known to be aggressive in their tumorigenic potential. In order to understand the 
effect of Activin-A knockdown on the tumor forming ability in MDA-MB-231 cells, 0.5 
million cells (optimal cell number generally used is 1-2 million) were injected 
subcutaneously in immunocompromised mice. The results showed that while control cells 
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gave rise to a tumor in 7 out of 10 animals, Activin-A knockdown cells could form a 
tumor in only 3 out of 10 animals. Also, the tumors formed by control cells were 
significantly larger by weight as compared to tumors formed by knockdown cells. 
Further, immunohistochemistry showed that tumors formed by MCF-7 cells 
overexpressing Activin-A have higher Ki-67 percentage as compared to control tumors. 
One of the factors known to be important for tumor growth is VEGF, which leads to 
recruitment of blood vessels and hence providing nourishment to the tumor cells. Hence 
Activin-A regulation of VEGF expression was evaluated next. Activin-A treatment or its 
stable overexpression in MCF-7 cells resulted in increased VEGF expression in these 
cells. This was also confirmed by VEGF promoter activity assay. To assess if Activin-A 
can play a role in metastatic spread of cancer cells, tail vein injection of Activin-A 
overexpressing MCF-7 cells was performed in immunocompromised mice. Even though 
no significant difference was found in the number of nodules formed by control or 
Activin-A overexpressing cells, it was observed that Activin-A overexpressing cells 
formed much bigger nodules as compared to the control cells. This suggests that Activin-
A may play an important part in the establishment of metastases from the disseminated 
cancer cells. Tumor forming ability of cancer cells and aggressiveness of various cancers 
has been associated with the presence of cells having stem-like phenotype. In this 
direction, CD44
high 
and CD24
low 
expression status was analysed upon overexpression and 
knockdown of Activin-A in MCF-7 and MDA-MB-231 cells respectively. FACS analysis 
of Activin-A overexpressing MCF-7 cells and Activin-A knockdown MDA-MB-231 cells 
shows that Activin-A expression leads to enrichment of breast cancer stem-like cells. 
In conclusion, this study highlights the importance of Activin-A signaling pathway in the 
progression of breast tumors. It is also important to note the role of SMAD signalling in 
the progression of breast cancers since these effectors are common between TGF-β, 
Activin and nodal factors, which have been shown to be involved in cancer progression in 
a context dependent manner.  
  
